| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.37▲ | 2.36▲ | 2.36▲ | 2.35▲ | 2.37▲ |
| MA10 | 2.36▲ | 2.37▲ | 2.37▲ | 2.32▲ | 2.34▲ |
| MA20 | 2.37▲ | 2.37▲ | 2.37▲ | 2.39▼ | 2.24▲ |
| MA50 | 2.37▲ | 2.33▲ | 2.32▲ | 2.33▲ | 2.26▲ |
| MA100 | 2.36▲ | 2.34▲ | 2.39▼ | 2.24▲ | 2.38▼ |
| MA200 | 2.34▲ | 2.37▲ | 2.34▲ | 2.25▲ | 3.92▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.000▲ | -0.004▼ | -0.003▼ | -0.005▼ | 0.021▲ |
| RSI | 52.365▲ | 54.774▲ | 54.553▲ | 50.870▲ | 54.843▲ |
| STOCH | 95.833▲ | 33.824 | 35.185 | 56.165 | 52.372 |
| WILL %R | 0.000▲ | -50.000 | -50.000 | -41.935 | -47.682 |
| CCI | 222.430▲ | -18.462 | 7.000 | 42.622 | 52.228 |
|
Thursday, October 23, 2025 06:09 AM
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a clinical-stage pharmaceutical company, today issued a Letter to Shareholders from its President and Chief ...
|
|
Sunday, October 19, 2025 06:01 AM
Detailed price information for Scilex Holding Co. (SCLX-Q) from The Globe and Mail including charting and trades.
|
|
Saturday, October 18, 2025 06:44 PM
Behind the scenes, Oramed is executing measures to strengthen its financial foundation. A recent transaction with Scilex Holding injected $13 million into company coffers through the repurchase of ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 27/10/25 | 2.31 | 2.43 | 2.31 | 2.37 | 149,727 |
| 24/10/25 | 2.37 | 2.43 | 2.32 | 2.39 | 136,448 |
| 23/10/25 | 2.29 | 2.45 | 2.27 | 2.37 | 243,887 |
| 22/10/25 | 2.32 | 2.33 | 2.225 | 2.29 | 78,048 |
| 21/10/25 | 2.28 | 2.40 | 2.25 | 2.34 | 69,192 |
| 20/10/25 | 2.21 | 2.31 | 2.21 | 2.29 | 74,598 |
| 17/10/25 | 2.21 | 2.27 | 2.21 | 2.23 | 60,833 |
| 16/10/25 | 2.28 | 2.30 | 2.19 | 2.27 | 190,814 |
| 15/10/25 | 2.35 | 2.36 | 2.20 | 2.27 | 225,077 |
| 14/10/25 | 2.41 | 2.43 | 2.32 | 2.36 | 153,110 |
|
|
||||
|
|
||||
|
|